A prospective, open-label, single-arm, multicenter study evaluating the efficacy of Xanomeline/Trospium (XT) on cognitive impairment after 24 and 52 weeks of treatment in adult participants with schizophrenia.

Status

Withdrawn

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-523060-20-00

Enrollment

Registered

2026-03-03

Start date

Unknown

Completion date

Unknown

Last updated

2026-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia

Brief summary

Change from baseline to week 24 in the BACS composite cognitive score.

Detailed description

Change from baseline to week 24 in the PANSS negative subscale.

Interventions

DRUGKarXT

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
Change from baseline to week 24 in the BACS composite cognitive score.	—

Secondary

Measure	Time frame
Change from baseline to week 24 in the PANSS negative subscale.	—

Outcome results

None listed

Source: EU CTIS · Data processed: Mar 5, 2026